Postmarketing surveillance: Strengths and limitations. The flucloxacillin-dicloxacillin story

Medical Journal of Australia

Volumn 170, Issue 6, 1999, Pages 270-273

  McNeil, John J ^a   Grabsch, Elizabeth A ^b   McDonald, Malcolm M ^c  

^a ALFRED HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c GEELONG HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DICLOXACILLIN; FLUCLOXACILLIN;

AUSTRALIA; DRUG MONITORING; DRUG SAFETY; JAUNDICE; NEW ZEALAND; POSTMARKETING SURVEILLANCE; RISK; SHORT SURVEY; UNITED KINGDOM;

EID: 0033559723     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1999.tb127751.x     Document Type: Short Survey

References (20)

1. Faich GA Adverse drug reaction monitoring. N Engl J Med 1986; 314: 1589-1592.
2. Venning GR. Rare and serious adverse reactions Med Toxicol Adverse Drug Experience 1987; 2: 239-241.
3. Roeser HP, Rohan AP. Post-marketing surveillance of drugs. The spontaneous reporting scheme: role of the Adverse Drug Reactions Advisory Committee. Med J Aust 1990; 153: 720-726.
4. Ten Pas A, Quinn EL. Cholestatic hepatitis following the administration of sodium oxacillin. JAMA 1965; 191: 674-675.
5. Lobatto S, Dijkrnans BA, Mattie H, Van Hooff JP. Flucloxacillin-associated liver damage. Neth J Med 1982; 25: 47-48.
6. Turner IB, Eckstein RP, Riley JW, Lunzer MR. Prolonged hepatic cholestas s after flucloxacillin therapy. Med J Aust 1989; 151: 701-705.
7. Miros M, Kerlin P, Walker N, Harris O. Flucloxacillin induced delayed cholestatic hepatitis. Aust N Z J Med 1990; 20: 251-253.
8. Adverse Drug Reactions Advisory Committee of the Australian Drug Evaluation Committee. Flucloxacillin hepatitis. Aust Adverse Drug Reactions Bull 1990; 9 (1): 3.
9. Adverse Drug Reactions Advisory Committee of the Australian Drug Evaluation Committee. Update on flucloxacillin-induced hepatitis. Adverse Drug Reactions Bull 1992; 11 (1): 2.
10. Adverse Drug Reactions Advisory Committee of the Australian Drug Evaluation Committee. Fatal hepatic reactions to flucloxacillin. Adverse Drug Reactions Bull 1994; 13(3): 10-11.
11. Pillans PI. Drug associated hepatic reactions in New Zealand 21 years experience. N Z Med J 1996; 109: 315-319.
12. Olsson R, Wiholm BE, Sand C. et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992; 15: 154-161.
13. Derby LE, Jick H, Henry DA. Dean AD Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993; 158: 596-600.
14. Jick H, Derby LE, Dean AD, Henry DA Flucloxacillin and cholestatic hepatitis [letter]. Med J Aust 1994. 160:525.
15. Fairley CK, McNeil JJ, Desmond P, et al. Risk factors for development of flucloxacillin associated jaundice. BMJ 1993; 306: 233-235.
16. Australian Drug Evaluation Committee Correspondence (94/2355) to pharmaceutical industry. Re: Dicloxacillin. 28 June 1994.
17. Commonwealth Department of Health and Family Services. Schedule of Pharmaceutical Benefits. Canberra: AGPS, August 1994.
18. Boyd IW. Adverse drug reactions of dicloxacillin versus flucloxacillin. Proceedings of (ASCEPT) Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Vol 5. Sydney: ASCEPT. 1998: 60.
19. Rossi AC, Hsu JP, Faich GA. Ulcerogenicity of piroxicam. an analysis of spontaneously reported data. Br Med J Clin Res Ed 1987; 294: 147-150.
20. Stolberg SG. The nation the numbering of America, medical IDs end privacy (or what's left of it). New York Times 26 July 1998